New generation in weight-loss therapies targets overweight
Oxford Medical Products (OMP) has announced additional three-month clinical trial results for Sirona, its weight-loss treatment targeting people who are overweight or have class I obesity (BMI 25-35) and those transitioning off GLP-1 medication.
The clinical trial took place across three NHS hospitals in the UK and showed participants taking Sirona continued to experience sustained weight loss at the three-month mark.
People with class I obesity (BMI 30-35) on average lost more than 6.3% total body weight whilst on Sirona, without any ongoing diet and exercise support.
Further analysis of the 12-week data showed that participants on Sirona consumed on average 400 fewer calories per day than those on placebo.
These early data suggest that Sirona could achieve an average of 10-12% total body weight loss at 52 weeks.
Sirona is a dual-polymer hydrogel pill that, once swallowed, expands rapidly in the stomach to suppress appetite by reducing the available volume for food.
There were no serious adverse events reported in the trial, Sirona was well tolerated (95% of patients adhered to the dosing regimen at 12 weeks) and demonstrated a good safety and side effect profile.
Many overweight patients do not qualify for Wegovy
Dr Camilla Easter, CEO of Oxford Medical Products, said: “Our approach is highly differentiated and complementary to existing and emerging GLP-1 therapies, offering a unique, tailored solution—particularly for individuals in the overweight category. Sirona provides an optimal risk-benefit profile, enabling safe and cost-effective weight loss. In the coming years, we will advance two pivotal trials focused on both weight loss and long-term weight maintenance.”
In 2017, 39% of deaths related to high BMI occurred in people who were non-obese (BMI <30). However, the vast majority of these individuals do not have access to the new weight loss drugs (GLP-1s).
Wegovy and Zepbound indicate use in individuals with a BMI 30-40 or 27 with at least one weight-related comorbidity, whereas Sirona is targeted at patients with a BMI 25-40.
Dr Asif Humayun, an endocrinologist with the NHS, commented: “Sirona represents a new generation in weight-loss therapeutics, specifically for obese patients and their resulting comorbidities. In contrast to traditional weight-loss measures, Sirona’s hydrogel system offers a method that is non-systemic and potentially lifelong. The early results of the trial in the initial stages have been promising, particularly with how it works with the natural processes of the body to regulate weight without merely pharmacologic drugs. It can be a game-changer for patients who considered other options insufficient or unsustainable in the long term.”
Oxford Medical Products is planning to advance Sirona into a larger pivotal trial in both the US and UK later this year.
Diana Spencer, Senior Digital Content Editor, DDW
